Search
Now showing items 1-2 of 2
Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients
The objective of this research was to optimize the tasted-masked microparticles for orally disintegrating tablets containing donepezil hydrochloride using quality risk assessment and design of experiment approaches. The ...
Donepezil—an updated review of challenges in dosage form design
Donepezil hydrochloride (DPH) was first launched in 1997 as a choline esterase inhibitor (ChEI). The USFDA has approved it for treatment of Alzheimer's disease since it effectively enhances cholinergic activity by slowing ...